The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.
Abstract
PURPOSE: To characterize and model the disposition of paclitaxel in humans and define a pharmacodynamic relationships between paclitaxel disposition and its toxicity and efficacy. PATIENTS AND METHODS: Paclitaxel pharmacokinetics were studied in 55 courses of therapy in 30 patients. Paclitaxel was administered at 135 mg/m2 or 175 mg/m2 by either a 3- or a 24-hour infusion schedule to patients with advanced ovarian cancer (n = 15), or at 225 mg/m2 by 3-hour infusion to patients with advanced breast cancer (n = 15). Paclitaxel and 6 alpha-hydroxylpaclitaxel were quantified by high-performance liquid chromatography (HPLC). Pharmacokinetics were assessed by noncompartmental and model-dependent methods. Pharmacodynamic correlations were evaluated statistically and by regression models. RESULTS: Paclitaxel disposition is nonlinear in humans and, on the 3-hour schedule, 6 alpha-hydroxylpaclitaxel was identified in the plasma of all patients treated. The plasma disposition of paclitaxel and 6 alpha-hydroxylpaclitaxel was well described by a model that featured multiple nonlinear processes. Neutropenia was not related to the areas under the curves (AUCs) of paclitaxel or 6 alpha-hydroxylpaclitaxel, or to palitaxel peak concentrations (Cmax). Neutropenia was related to the duration that plasma concentrations were > or = 0.05 mumol/L, a relationship that is well described by a sigmoid maximum response (Emax) model. CONCLUSION: The disposition of paclitaxel in humans is nonlinear. Paclitaxel metabolism to 6 alpha-hydroxylpaclitaxel is likely an important detoxification pathway. Myelosuppression is related to the duration that plasma paclitaxel concentrations are > or = 0.05 mumol/L. Trials of new doses and schedules of paclitaxel should take into account its nonlinear disposition to rule out adverse clinical consequences, especially if the drug is administered by short infusion. Our pharmacokinetic model should prove to be a powerful tool in predicting paclitaxel disposition, regardless of dose and schedule, and should facilitate further pharmacodynamic investigations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
DeLean, A., Munson, P. J., & Rodbard, D. (1978) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1978.235.2.e97 · Cited by 2,374
Taxol: A Novel Investigational Antimicrotubule Agent
Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,090
THE IMPACT OF NATIONAL CANCER ACT
(1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797 · Cited by 796
Eisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E., Kerr, I., Vermorken, J. B., Buser, K., & Colombo, N. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2654 · Cited by 626
Self-citationA program package for simulation and parameter estimation in pharmacokinetic systems
D'argenio, D. Z., & Schumitzky, A. (1979) · Computer Programs in Biomedicine · doi:10.1016/0010-468x(79)90025-4 · Cited by 471
Phase I clinical and pharmacokinetic study of taxol.
Wiernik, P. H., Schwartz, E. L., Strauman, J. J., Dutcher, J. P., Lipton, R. B., & Paietta, E. M. (1987) · PubMed · Cited by 455
LAGRAN program for area and moments in pharmacokinetic analysis
Rocci, M. L., & Jusko, W. J. (1983) · Computer Programs in Biomedicine · doi:10.1016/0010-468x(83)90082-x · Cited by 414
Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.
Rowinsky, E. K., Donehower, R. C., Jones, R. J., & Tucker, R. W. (1988) · PubMed · Cited by 368
Huizing, M. T., Keung, A. C., Rosing, H., van der Kuij, V, ten Bokkel Huinink, W. W., Mandjes, I. M., Dubbelman, A. C., Pinedo, H. M., & Beijnen, J. H. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2127 · Cited by 308
Wagner, J. G. (1968) · Journal of Theoretical Biology · doi:10.1016/0022-5193(68)90188-4 · Cited by 305
Steimer, J.-L., Mallet, A., Golmard, J.-L., & Boisvieux, J.-F. (1984) · Drug Metabolism Reviews · doi:10.3109/03602538409015066 · Cited by 275
Wiernik, P. H., Schwartz, E. L., Einzig, A., Strauman, J. J., Lipton, R. B., & Dutcher, J. P. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1232 · Cited by 275
Cresteil, T., Monsarrat, B., Alvinerie, P., Tréluyer, J., Vieira, I., & Wright, M. (1994) · PubMed · Cited by 257
Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
Rowinsky, E. K., Burke, P. J., Karp, J. E., Tucker, R. W., Ettinger, D. S., & Donehower, R. C. (1989) · PubMed · Cited by 196
Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Kohn, E. C., Sarosy, G., Bicher, A., Link, C., Christian, M., Steinberg, S. M., Rothenberg, M., Adamo, D. O., Davis, P., Ognibene, F. P., et al. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.1.18 · Cited by 187
A phase I trial of taxol given by a 6-hour intravenous infusion.
Brown, T., Havlin, K., Weiss, G., Cagnola, J., Koeller, J., Kuhn, J., Rizzo, J., Craig, J., Phillips, J., & Von Hoff, D. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.7.1261 · Cited by 180
Sarosy, G., Kohn, E., Stone, D. A., Rothenberg, M., Jacob, J., Adamo, D. O., Ognibene, F. P., Cunnion, R. E., & Reed, E. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1165 · Cited by 179
Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.
Sonnichsen, D. S., Hurwitz, C. A., Pratt, C. B., Shuster, J. J., & Relling, M. V. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.3.532 · Cited by 137
Longnecker, S. M., Donehower, R. C., Cates, A. E., Chen, T. L., Brundrett, R. B., Grochow, L. B., Ettinger, D. S., & Colvin, M. (1987) · PubMed · Cited by 112
Phase I study of taxol administered as a short i.v. infusion daily for 5 days.
Grem, J. L., Tutsch, K. D., Simon, K., Alberti, D. B., Willson, J. K. V., Tormey, D. C., Swaminathan, S., & Trump, D. L. (1987) · PubMed · Cited by 102
Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation.
Kumar, G. N., Walle, U. K., & Walle, T. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38591-5 · Cited by 82
Hepatic metabolism and biliary excretion of Taxol in rats and humans.
Monsarrat, B., Alvinerie, P., Wright, M. R., et al. (1993) · PubMed · Cited by 72
Jamis‐Dow, C., Klecker, R. W., Sarosy, G., Reed, E., & Collins, J. M. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686022 · Cited by 61
Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines.
Gianni, L., Capri, G., Munzone, E., & Straneo, M. (1994) · PubMed · Cited by 34
Self-citation
Cited by
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Pascucci, L., Coccè, V., Bonomi, A., Ami, D., Ceccarelli, P., Ciusani, E., Viganò, L., Locatelli, A., Sisto, F., Doglia, S. M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.042 · Cited by 846
Self-citationKim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Protein nanoparticles as drug carriers in clinical medicine
Hawkins, M. J., Soon-Shiong, P., & Desai, N. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.044 · Cited by 779
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
Rowinsky, M. (1997) · Annual Review of Medicine · doi:10.1146/annurev.med.48.1.353 · Cited by 721
Metadata
- Authors
- Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganó, L., Lacatelli, A., Bonadonna, G., & Egorin, M. J.
- Venue
- Journal of Clinical Oncology
- Published
- 1995-01
- Volume
- 13
- Issue
- 1
- Pages
- 180-190
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1836451026
- Cited by
- 553
- References
- 25
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.